Form 4: Medifast Director Michael Hoer Reports Grant of Restricted Stock Units

Medifast, Inc. Director Michael A. Hoer has reported the acquisition of 11,168 restricted stock units as part of his annual director compensation, vesting in June 2026.

Summary

• Michael A. Hoer, a Director of Medifast, Inc. (MED), reported the acquisition of 11,168 shares of common stock.
• The transaction occurred on June 25, 2025.
• These shares were acquired as restricted stock units (RSUs) at a price of $0 per share, indicating a compensation grant.
• The RSUs were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated, in connection with the payment of annual director fees.
• Each RSU represents the right to receive one share of Medifast's common stock.
• The shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan.
• These RSUs will vest in full on June 25, 2026.
• Following this transaction, Michael A. Hoer beneficially owns 26,139.473 shares of Medifast common stock.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 reporting a standard director compensation grant. It is neutral in sentiment as it reflects an expected operational event rather than a positive or negative financial or strategic development.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value through equity compensation.
• It indicates a standard compensation practice for board members, reflecting ongoing corporate governance.

Negatives

• No specific negative aspects are indicated by this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The 11,168 restricted stock units granted to Director Michael A. Hoer are scheduled to vest in full on June 25, 2026, indicating a future increase in his direct share ownership upon vesting.

Industry Context

This Form 4 filing represents a routine compensation event for a director, common across publicly traded companies. The grant of restricted stock units is a standard practice in executive and director compensation, aligning their interests with long-term company performance and shareholder returns. It does not provide specific insights into broader industry trends or competitive positioning beyond standard corporate governance practices.

Comparison to Industry Standards

• The grant of restricted stock units as part of director compensation is a common practice among U.S. public companies, including those in the health and wellness or consumer packaged goods sectors where Medifast operates.
• Companies like Herbalife Nutrition Ltd. (HLF) or WW International, Inc. (WW) also utilize equity-based compensation for their directors to incentivize long-term performance and align interests with shareholders.
• The specific number of units granted (11,168) would typically be benchmarked against peer companies' director compensation packages, considering Medifast's market capitalization and the director's specific responsibilities, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of 11,168 restricted stock units to Michael A. Hoer, a Director of Medifast, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors. This is a standard and disclosed form of related party dealing.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns the director's long-term interests with those of shareholders, potentially encouraging decisions that enhance shareholder value. It also represents a minor dilution of existing shares upon vesting.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The 11,168 restricted stock units granted to Michael A. Hoer are scheduled to vest in full on June 25, 2026.

Key Dates

Keywords

Medifast, MED, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU, Director compensation, Equity grant, Michael Hoer, Share ownership